LDE225

Phase 1/2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Medulloblastoma

Conditions

Medulloblastoma, Rhabdomyosarcoma, Neuroblastoma, Hepatoblastoma, Glioma, Astrocytoma

Trial Timeline

Feb 1, 2011 → Oct 1, 2014

NCT ID

NCT01125800

About LDE225

LDE225 is a phase 1/2 stage product being developed by Novartis for Medulloblastoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01125800. Target conditions include Medulloblastoma, Rhabdomyosarcoma, Neuroblastoma.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02195973	Phase 1	Completed	Sep 1, 2014	Sep 30, 2017	Recurrent Ovarian Cancer
NCT02151864	Phase 1	Completed	Jul 1, 2014	Sep 1, 2017	Hepatocellular Carcinoma
NCT02086513	Phase 1	Terminated	Apr 1, 2014	Dec 1, 2016	Graft Versus Host Disease
NCT02002689	Phase 2	Terminated	Feb 1, 2014	Mar 1, 2015	PTCH1 or SMO Activated Solid and Hematologic Tumors
NCT01826214	Phase 2	Completed	May 1, 2013	May 1, 2015	Acute Leukemias
NCT01764776	Phase 1	Completed	Mar 1, 2013	Mar 1, 2015	Normal Hepatic Function
NCT01529450	Pre-clinical	Completed	Feb 1, 2012	Aug 1, 2013	Basal Cell Carcinoma
NCT01327053	Phase 2	Completed	Jun 29, 2011	Jun 29, 2018	Basal Cell Carcinoma
NCT01125800	Phase 1/2	Completed	Feb 1, 2011	Oct 1, 2014	Medulloblastoma
NCT01208831	Phase 1	Completed	Oct 1, 2010	Oct 1, 2013	Advanced Solid Tumor Cancers
NCT00880308	Phase 1	Completed	Mar 1, 2009	Jul 1, 2013	Advanced Solid Tumor Cancers

Competing Products

9 competing products in Medulloblastoma

See all competitors

Product	Company	Stage	Hype Score
LY2940680 + LY2940680	Eli Lilly	Phase 1	33
LDE225 + TMZ	Novartis	Phase 2	52
Lomustine + Vincristine + Cisplatin + Cyclophosphamide + Mesna + Vincristine	Brain Biotech	Phase 1	25
Modified Measles Virus + Modified Measles Virus Lumbar Puncture	Brain Biotech	Phase 1	25
CX 4945	Brain Biotech	Phase 1/2	33
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years + SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years + SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years	Brain Biotech	Phase 1	25
PEP-CMV	Brain Biotech	Phase 1	25
Apatinib Combined With Temozolomide and Etoposide Capsules	Brain Biotech	Phase 2	44
Irinotecan + Temozolomide + Bevacizumab + Omburtamab I-131 + Liothyronine + SSKI + Dexamethasone + Antipyretic + Antihistamine + anti-emetics	Brain Biotech	Phase 2	44

Other Products from Novartis

LCZ696Approved

zoledronic acidApproved

NateglinideApproved

TenofovirApproved

FTY720Approved